The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical

The Cancer Letter wins investigative, design awards

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The Cancer Letter won four 2018 Dateline Awards from the Washington, D.C. Chapter of the Society of Professional Journalists:

  • Investigative Journalism, Newsletter/Trade Publications, first place, for “A Coup D’état, and a $12M Deal at the University of Utah,” by Paul Goldberg and Matthew Ong (The Cancer Letter, April 21, April 28, May 5, 2017)

  • Front Page Design, Newsletter/Trade Publications, first place, for “43 Years Later: A Redesign of The Cancer Letter,” By Jacqueline Ong and Katherine Goldberg

  • Photo Illustration, Newsletter/Trade Publications, first place, for “Oncology as Art in 2017,” by Katherine Goldberg

  • Series, Newsletter/Trade Publications, finalist, for “Real-World Data: A New Frontier in Cancer Bioinformatics,” by Matthew Ong (The Cancer Letter, June 2, June 9, 2017)

This is the first time The Cancer Letter has won design awards. Every week, our illustrator, Katherine Goldberg, offers a smart, irreverent take on events in oncology. Jacqueline Ong, our designer, undertook a snazzy redesign of the PDF version of The Cancer Letter.

Here are a few of The Cancer Letter’s award-winning covers:

Table of Contents

YOU MAY BE INTERESTED IN

Clinical

Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.”

The long-awaited results from the RASolute 302 trial—a phase III clinical trial evaluating daraxonrasib, a RAS inhibitor, for the treatment of patients with previously treated, metastatic pancreatic ductal adenocarcinoma—have been read out. 
By Jacquelyn Cobb
Cancer History ProjectEditorial

Calabresi’s “Cancer at a Crossroads” report was the first step toward historic doubling of the NIH budget
Fox Chase’s Winn contemplates Crossroads 2.0

At a lecture at Yale Cancer Center recently, Robert A. Winn brandished a copy of a 32-year old booklet titled “Cancer at a Crossroads: A Report to Congress for the Nation,” using it as a show-and-tell prop in arguing that America’s cancer program is once again at a crossroads and therefore in urgent need of strategic thinking (The Cancer Letter, April 10, 2026).
By Paul Goldberg
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account